- Trial phase
- Approved
- Time to market
- Already approved and commercially marketed since 2011.
- Why 4/10
- EXPAREL is already FDA-approved and commercially marketed with no pending regulatory decision or pivotal readout. The next hard catalyst is the closing of the Viatris acquisition (a corporate M&A event, not a drug catalyst), expected by end of 2026. Per the rubric, an approved drug with no pending binary drug catalyst scores 3-5; the default of 4 applies.
EXPAREL is a mature, approved product with no upcoming binary drug catalyst. The stock trades at the $36.50 Viatris acquisition price, so the near-term move depends entirely on deal closing (expected by end of 2026). Watch for the Ninth Circuit royalty ruling's impact on EXPAREL margins and any updates on the tender offer's regulatory clearance.
Price Chart
Executive Summary
EXPAREL (bupivacaine liposome injectable suspension) is Pacira BioSciences' flagship non-opioid postsurgical pain drug, approved by the FDA since 2011 with label expansions as recent as November 2023. It is a mature, marketed product that generates the vast majority of Pacira's revenue (~78% in 2024). The stock is currently being acquired by Viatris for $36.50 per share in a $1.65 billion cash deal expected to close by end of 2026, and trades essentially at that price. Key developments include patent settlements pushing generic competition to 2030, expanding reimbursement (UnitedHealthcare, NOPAIN Act), a new EU/UK commercialization partnership, and a recent adverse Ninth Circuit ruling that could require Pacira to resume royalty payments on EXPAREL. With no upcoming binary drug catalyst, the investment thesis is dominated by the pending acquisition.
How It Works
EXPAREL is a long-acting, non-opioid local anesthetic injected at the surgical site to manage postsurgical pain. It uses a liposomal (DepoFoam) delivery system that encapsulates bupivacaine and releases it slowly over several days, providing extended pain relief without the opioid-related side effects like addiction and respiratory depression.
Trial Status
EXPAREL is FDA-approved and commercially marketed. The most recent label expansion was November 2023 for two additional nerve block indications. Ongoing real-world evidence studies continue to support its use in various surgical settings.
The Two-Sided Case
Upcoming Catalysts
- Closing of Viatris acquisition (expected by end of 2026) - the tender offer commenced October 30, 2026
- District Court recalculation of pre-judgment interest on the RDF royalty dispute following the Ninth Circuit's November 6, 2026 ruling
- Potential further appeals in the RDF royalty case
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Pacira BioSciences, Inc. 8-K PCRX ·Originating report